# Humanis Saglık Anonim Sirketi: Phase 1 study in Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases (36 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Humanis Saglık Anonim Sirketi |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets |
| NCT ID | NCT07872358 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Type 2 Diabetes Mellitus (T2DM); Cardiovascular Diseases |
| Intervention types | drug |
| Target enrollment | 36 |
| Site countries | India |
| Posted | 2026-10-13 |
| Planned start | 2026-06-07 |
| Event | Newly registered study |
| Event date | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07872358). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.